Bodal ChemicalsQ2 FY23

Bodal Chemicals Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹155.7P/E: 13.6Market Cap: ₹2.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Bodal Chemicals aims to double dyestuff volumes in the next 2-3 years, particularly leveraging growth in Turkey and surrounding countries.
  • The company plans to diversify from core Dyestuff and Dye Intermediate business towards specialty chemicals like benzene derivatives, which have higher margins (18-25% EBITDA).
  • Chlor Alkali business is expected to ramp up capacity utilization to 90% by January 2023, supporting revenue growth.
  • Saykha greenfield project for benzene derivatives is expected to start trial runs in Q2 FY '24, followed by sulphuric acid trials by Q4 FY '24.
  • Bodal targets INR 400+ crore turnover from Chlor Alkali and INR 500+ crore from benzene derivatives and sulphuric acid combined once projects stabilize.
  • Overall, company aims for a blended EBITDA margin increase to approximately 14-15% with new integrated product chains and improved cost structures.
  • Expansion focuses on reducing dependence on volatile dye intermediate business, bringing it down to 30-40% of total revenue.

See what Bodal Chemicals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
  • The company is focused on executing existing projects like the Saykha greenfield project and expanding capacities.
  • They have put some smaller projects on hold to manage capex prudently amid rising steel and cement prices.
  • Ankit Patel mentioned not wanting to over-leverage and being cautious about project cost overruns.
  • The strategy includes growing organically via capacity ramp-ups, technology upgrades, and some targeted smaller expansions rather than aggressive acquisitions or new fundraising.
  • Thus, based on the call, no immediate plans for raising funds via debt or equity were indicated.

See what Bodal Chemicals management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The Saykha greenfield project for benzene derivatives and sulphuric acid is ongoing, with trial runs expected in Q2 FY '24 (benzene derivatives) and Q4 FY '24 (sulphuric acid).
  • Some small projects with capex around INR 40 crores are put on hold; to be compensated by investments in better technology for PNCB, ONCB, and sulphuric acid.
  • Revised project cost for Saykha may increase from INR 400 crores to INR 500+ crores, mainly due to steel and shipment price increases.
  • Certain benzene downstream derivative projects like MPDSA, PNA, 2,4-DNCB are on hold, pending outlook evaluation.
  • Focus is on integrated product chains for cost efficiency and higher margins in pharma and agrochemical segments.
  • No aggressive acquisitions currently; growth planned through greenfield expansions and vertical/horizontal integrations, especially in Chlor Alkali, benzene derivatives, and sulphuric acid.
  • Several sulfuric acid projects under consideration for forward integration in the next phase.

Track Bodal Chemicals — get its next earnings analysis in your feed

How does Bodal Chemicals rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisBodal Chemicals
Rev 3Mar 1

How does Bodal Chemicals rank in Chemicals & Petrochemicals?

Compare Bodal Chemicals against every Chemicals & Petrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →